A recent medical study showed that some medications used to treat diabetes, which are also prescribed to heart and kidney patients, may be associated with a slight increase in blood hemoglobin levels and red blood cell counts, along with changes in some iron markers, while the health implications of these changes require further research.
According to the study published in the medical journal JAMA yesterday Saturday, the research was conducted by a team from the University Medical Center in the Dutch city of Groningen, with participation from researchers from medical and academic institutions in several countries, including Spain, the United States, Italy, Switzerland, and Australia.
The analysis included 85 clinical trials involving more than 70,000 people, and the results showed a limited increase in some blood markers among people who used these medications compared to others. The study included drugs belonging to the class of sodium-glucose cotransporter 2 inhibitors, including empagliflozin, dapagliflozin, and canagliflozin.
The researchers clarified that the results contribute to understanding the impact of these medications on blood markers and iron metabolism, but they do not necessarily mean that they treat anemia or that the recorded changes provide additional health benefits, which necessitates further studies to determine their medical implications.
Source: Syrian Arab News Agency (SANA)
Comments (0)